Murine typhus in central Greece: epidemiological, clinical, laboratory, and therapeutic-response features of 90 cases  by Chaliotis, George et al.
International Journal of Infectious Diseases 16 (2012) e591–e596Murine typhus in central Greece: epidemiological, clinical, laboratory, and
therapeutic-response features of 90 cases
George Chaliotis a, Evangelos I. Kritsotakis b, Anna Psaroulaki b, Yannis Tselentis b, Achilleas Gikas b,c,*
aDepartment of Internal Medicine, General Hospital of Chalkida, Evia, Greece
b Laboratory of Clinical Bacteriology, Parasitology, Zoonoses and Geographical Medicine, University of Crete, Heraklion, Crete, Greece
cUniversity Hospital of Heraklion, 1352/71110, Crete, Greece
A R T I C L E I N F O
Article history:
Received 11 October 2011
Accepted 12 March 2012
Corresponding Editor: William Cameron,
Ottawa, Canada
Keywords:
Murine typhus
Rickettsia typhi
Clinical aspects
Diagnosis
Therapy
Complications
S U M M A R Y
Objectives: To document and evaluate the clinico-epidemiological proﬁle of murine typhus during the re-
emergence of the disease in a previously endemic focus in central Greece.
Methods: This was a 5-year, hospital-based, observational study, in which 90 adult patients with murine
typhus were prospectively identiﬁed and studied.
Results: Most cases of the disease occurred in rural (52%) and semi-urban (34%) settings, with a seasonal
frequency peak during the late summer. The triad of fever, headache, and rash was present in 64% of the
patients within 2 days of hospital admission. Normal white blood cell counts (63%), thrombocytopenia
(81%), and a high erythrocyte sedimentation rate (93%) were the main hematological ﬁndings upon
presentation. Elevated aminotransferases (>84%), hypoalbuminemia (81%), and hyponatremia (36%)
were prominent biochemical abnormalities. Pulmonary, neurological, and renal complications were
noted in 26% of the patients and subsided after speciﬁc treatment. The duration of fever was shorter in
patients treated with doxycycline (median 3 days) compared to oﬂoxacin (p = 0.001) or doxycycline plus
oﬂoxacin (p = 0.009).
Conclusions: Murine typhus has the potential to cause signiﬁcant morbidity. Awareness of the disease in
endemic areas, early recognition of its clinical and laboratory features, and prompt administration of
effective treatment are key factors to prevent potentially severe complications.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Murine or endemic typhus (MT) is a ﬂea-borne illness caused by
Rickettsia typhi, an obligate intracellular parasite that lives in the
cytoplasm of the cells of the host.1,2 The classical transmission
cycle for MT is rat–ﬂea–rat, with commensal rats of the subgenus
Rattus (R. norvegicus and R. rattus) and their ﬂeas (Xenopsylla
cheopis) acting as the main reservoir and vector, respectively.1–3
Rats also serve as amplifying hosts by making R. typhi in their blood
available for the ﬂeas, which transmit the organism back to rats
during subsequent feeding.1,2 Humans are accidental hosts who
presumably become infected when R. typhi-infected ﬂea feces
contaminate a pruritic ﬂea-bite wound or the conjunctivae of the
host, or the respiratory tract via inhalation of dust containing
infective material.1–3 Transmission by different ﬂea species (the
cat ﬂea, Ctenocephalides felis) and from different reservoirs
(domestic cats and opossums) have been well documented in
some areas.4* Corresponding author. Tel.: +30 2810 375050; fax: +30 2810 392847.
E-mail address: gikas@med.uoc.gr (A. Gikas).
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http://dx.doi.org/10.1016/j.ijid.2012.03.010The clinical diagnosis of MT is challenging because the illness
presents with many non-speciﬁc symptoms and signs, and
conﬁrmation by serology may be too late to affect the clinical
decision.1–4 The clinical course varies from mild symptoms that
may not require hospitalization to severe illness that can result in
death. Disease severity has been associated with older age, delayed
diagnosis and treatment, glucose-6-phosphate dehydrogenase
deﬁciency, hepatic and renal dysfunction, central nervous system
abnormalities, and pulmonary compromise.2–4 Untreated patients
present symptoms and signs for 2–3 weeks, with up to 10%
requiring intensive care.3,4 The case fatality rate, although low with
the use of appropriate antibiotics (1%), can approach 4% in the
absence of speciﬁc treatment.4
MT occurs in environments ranging from hot and humid to cold
and montane or semiarid, but it is most prevalent in warm areas,
particularly in port cities and coastal urban regions, where high
populations of rodents are found.1–5 Endemic foci of MT remain in
the Mediterranean region, the southern USA, Southeast Asia, and
Western Australia.1–5 Sporadic cases and outbreaks of MT have
been reported worldwide, frequently involving travelers return-
ing from endemic areas.6 MT has been reported to have
re-emerged in formerly endemic areas,7–11 and it was recentlyses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. Monthly distribution of cases of murine typhus in central Greece (the
horizontal reference line (dotted) corresponds to the series median).
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this disease.12–14
MT re-emerged in Greece after four decades of absence, when
49 cases of the disease were reported on the island of Evia in
central Greece in 1985.15 The number of patients with MT who
were referred to the local hospital gradually diminished over the
following years and the disease was almost forgotten. However,
new cases of MT were again diagnosed on Evia in 1998. We
therefore conducted a 5-year, hospital-based, prospective surveil-
lance study to re-evaluate the evolution of epidemiological,
clinical, and therapeutic aspects of MT in the region, and to warn
physicians and the public health authorities of the re-emergence
and persistence of the disease in central Greece.
2. Patients and methods
2.1. Study population
We performed a 5-year prospective case-series study at the
General Hospital of Chalkida, a 200-bed tertiary-care institution
that serves a population of over 200 000 people on the island of
Evia in central Greece.
Our reference population included adult patients (18 years
old) for whom there was a clinical suspicion of MT and who were
admitted to the hospital between 2001 and 2005. The minimum
presumptive clinical criteria for MT were the presence of fever
(38 8C) and/or headache and/or skin rash, and the absence of any
other clinically identiﬁed cause of infection (e.g., pneumonia,
urinary tract or gastrointestinal infection). Three serum samples
were obtained from each patient suspected of being infected (on
admission, at 1 week after admission, and 3 weeks later) and were
assayed for the presence of antibodies against R. typhi by the
indirect immunoﬂuorescent antibody (IFA) test. IgG titers of
1:960 or IgM titers of 1:400 and/or a four-fold increase in the
titers between two successive assays were considered as indicative
of acute infection. A case of MT was deﬁned as a patient meeting
the minimum presumptive clinical criteria and having IFA
conﬁrmation. Serology was performed at the Laboratory of Clinical
Bacteriology, Parasitology, Zoonoses and Geographical Medicine of
the University of Crete.
Data collected and analyzed for each case of MT included
demographic and epidemiologic characteristics (date of hospital
admission, age, gender, occupation, and area of residence),
symptoms, signs and complications during the course of illness,
routine laboratory test results on admission, treatment data
(antibiotic regimen and time to defervescence), and outcome.
2.2. Statistical analysis
Categorical data are presented as counts and percentages.
Continuous data are reported as the mean value  standard
deviation (SD) or median value and interquartile range (IQR),
depending on the degree of skewness in the distributions. For log-
normally distributed data (such as serologic data), the geometric
mean and geometric standard deviation are used to summarize
location and dispersion. Continuous data were compared between
different patient groups using the unpaired t-test or the Mann–
Whitney test and categorical data were compared by use of the
Chi-square test or Fisher’s exact test where appropriate. Time-to-
event data were analyzed by Kaplan–Meier survival analysis and
the log-rank test. Ninety-ﬁve percent conﬁdence intervals (95% CI)
were calculated when appropriate. A p-value of less than 0.05
(two-tailed) was considered to indicate statistical signiﬁcance. The
data analysis was performed using SPSS version 16 (SPSS, Inc.,
Chicago, IL, USA).3. Results
3.1. Demographic and epidemiological features
Of the 174 patients who were suspected of MT during the 5-
year study period, 90 (51.7%) were conﬁrmed to have the disease
and were included in the study. The median patient age was 43
years (IQR 33–62, range 18–89 years) and 61 patients (67.8%) were
male.
The overall cumulative incidence of the disease was 0.43 cases
per 100 adult patients and 2.36 cases per 100 adult patients with
an acute-febrile illness who were admitted to the hospital during
the study period. Cases occurred throughout the year, but a
seasonal frequency peak was evident during the late summer
(Figure 1). All patients originated from within a 30-km area
surrounding the city of Chalkida, most frequently residing in rural
(52.2%) or semi-urban (34.4%) settings. Most patients were farmers
(40%), outdoor laborers and construction workers (14.4%), or
housewives (17.8%).
3.2. Clinical manifestations
The earliest symptom of illness was an abrupt onset of fever in
all cases, usually associated with chills (91.1%). Fever was
continuous and began a median of 3 days (IQR 2–4 days, range
2–6 days) before hospital admission. The maximum temperature
recorded upon presentation ranged from 38 to 41 8C, with a mean
of 39.5  0.5 8C. The median total duration of fever was 7 days (IQR 6–
8 days, range 5–10 days).
A frontal headache was noted for 79 (87.8%) patients; it began a
median of 2 days after the onset of fever (IQR 1–2, range 1–4 days)
and lasted for a median of 4 days (IQR 4–5, range 3–7 days). A rash
was noted for 62 (68.9%) patients; this was macular or
maculopapular, with a centrifugal spread over the trunk, sparing
the palms and soles. Rash began a median of 4 days after the onset
of fever (IQR 3–4, range 2–5 days) and lasted for a median of 3 days
(IQR 3–3, range 2–4 days). The classical triad of fever, headache,
and rash was present in 58 (64.4%) of the patients during their
illness; however 25 (27.8%) patients exhibited two of these signs
and seven (7.8%) had fever only. Other symptoms such as malaise,
anorexia, myalgia, arthralgia, nausea/vomiting, etc. were less
common. Sixteen patients (17.8%) had both spleen and liver
enlargement, while isolated liver or spleen enlargement was
Table 1
Clinical manifestations in 90 patients with murine typhus in central Greece
Clinical manifestations No. (%) of patients
Symptoms
Fever 90 (100)
Chills 82 (91.1)
Headache 79 (87.8)
Perspiration 76 (84.4)
Malaise 62 (68.9)
Anorexia 50 (55.6)
Myalgia 49 (54.4)
Arthralgia 33 (36.7)
Nausea/vomiting 30 (33.3)
Non-productive cough 29 (32.2)
Signs
Rash 62 (68.9)
Hepatomegaly 29 (32.2)
Splenomegaly 23 (25.6)
Conjunctivitis 19 (21.1)
Complications
Pulmonary involvement 15 (16.7)
Central nervous system involvement 10 (11.1)
Acute renal failure 7 (7.8)
Disseminated intravascular coagulation 2 (2.2)
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Clinical manifestations in the 90 patients are shown in Table 1.
The clinical course was complicated in 23 patients (25.6%) who
presented a total of 34 complications, including pulmonary
involvement in 15 cases (13 interstitial inﬁltrations and two
plural effusions), central nervous system involvement in 10 cases
(eight stupor and two coma), acute renal failure in seven cases, and
disseminated intravascular coagulation in two cases. Patients who
presented these complications were signiﬁcantly older than those
without complications (median (IQR) age, 65 (51–71) vs. 42 (28–
52), respectively, p < 0.001), while no difference according to
gender was observed (men, 69.6% vs. 67.2%, respectively,
p = 0.832).
3.3. Laboratory ﬁndings
Laboratory test results upon admission are summarized in
Table 2. Twenty-eight patients (31.1%) displayed anemia upon
admission. Only four patients (4.4%) had leukocytosis, butTable 2
Laboratory ﬁndings on admission in 90 patients with murine typhus in central Greece
Laboratory ﬁndings Median (IQR) 
Blood cell examination
White blood cells ( 109/l) 4.6 (3.8–6.2) 
Hemoglobin (g/dl) 12.3 (11.5–13.7) 
Platelets ( 109/l) 126.5 (97–146) 
Erythrocyte sedimentation rate (mm/h) 38 (32–52) 
Biochemical examination
Albumin (mg/dl) 3.4 (3.2–3.6) 
Creatinine (mg/dl) 1.1 (0.9–1.2) 
Creatinine phosphokinase (U/l) 145.5 (128–176) 
Lactate dehydrogenase (U/l) 283 (230–373) 
Aspartate aminotransferase (U/l) 52 (46–66) 
Alanine aminotransferase (U/l) 69 (56–87) 
g-Glutamyl transferase (U/l) 57.5 (42–76) 
Total bilirubin (mg/dl) 0.9 (0.7–1.2) 
Direct bilirubin (mg/dl) 0.3 (0.2–0.4) 
Total protein (g/dl) 6.2 (5.9–6.4) 
Potassium (mmol/l) 3.8 (3.6–4.2) 
Sodium (mmol/l) 136 (134–138) 
IQR, interquartile range.
a Number and percentage of patients with values below or above the normal cut-ofleukopenia was present in 29 cases (32.2%). Thrombocytopenia
was noted for 73 patients (81.1%). A high erythrocyte sedimenta-
tion rate was observed for 84 patients (93.3%).
The most prominent biochemical ﬁndings on admission were
hypoalbuminemia for 73 patients (81.1%) and a >1-fold elevation
of aspartate aminotransferase and alanine aminotransferase
observed in 76 (84.4%) and 79 patients (87.8%), respectively.
Signiﬁcant abnormalities in serum electrolyte values included
hyponatremia in 32 (35.6%) and hypokalemia in 13 (14.4%)
patients.
IFA test results in three serum samples taken on admission
(median 3 days, range 2–6 days after onset of fever), 1 week after
admission, and 3 weeks later, respectively, are shown in Table 3.
Serological conﬁrmation of MT was met for 14 patients (15.6%) in
the ﬁrst sample, 90 patients (100%) in the second sample, and 69
patients (76.7%) in the third sample. When serology data were
examined by age, none of the elderly patients (age 65 years) had
an IgG or IgM titer exceeding the cut-off titer during the ﬁrst week
of illness. In contrast, 20% of the non-elderly patients had a
serological conﬁrmation within the ﬁrst week of illness. No age-
related difference in antibody kinetics was observed in the second
and third serum samples. No association of the IFA antibody titers
with the presence of complications was observed.
3.4. Response to treatment and outcome
All patients received treatment on the day of admission: 73
patients (81.1%) were treated with doxycycline, 11 (12.2%) with
oﬂoxacin, and six patients (6.7%) received doxycycline plus
oﬂoxacin. Median times between the onset of fever and initiation
of treatment were similar for the three treatment options used: 3
days (range 2–6 days) for doxycycline, 3 days (range 2–5 days) for
oﬂoxacin, and 3.5 days (range 2–4 days) for doxycycline plus
oﬂoxacin (p = 0.216).
Fever returned to normal in a median of 3 days with
doxycycline (95% CI 2.8–3.2 days), 4 days with oﬂoxacin (95% CI
3.8–4.2 days), and 4 days with doxycycline plus oﬂoxacin (95% CI
3.6–4.4 days). Comparison of the three treatment groups using a
Kaplan–Meier survival analysis (Figure 2) showed that time to
defervescence was signiﬁcantly shorter in the group of patients
treated with doxycycline compared to those treated with oﬂoxacin
(p = 0.001) or those treated with doxycycline plus oﬂoxacinRange Reference cut-offa
Value No. (%)
1.7–13.0 <4 29 (32.2)
8.7–16.3 <12 28 (31.1)
34–510 <150 73 (81.1)
15–110 >20 84 (93.3)
2.7–4.6 <38 73 (81.1)
0.6–3.7 >1.3 12 (13.3)
56–317 >170 28 (31.1)
132–1386 >420 19 (21.1)
21–253 >38 76 (84.4)
2.5–285 >41 79 (87.8)
13–397 >61 44 (48.9)
0.3–3.4 >0.6 79 (87.8)
0.0–3.1 >0.2 66 (73.3)
3.9–6.9 <6 32 (35.6)
2.9–6.2 <3.6 13 (14.4)
127–146 <135 32 (35.6)
f value as indicated.
Table 3
Indirect ﬂuorescent antibody test results in 90 patients with murine typhus in central Greecea
First serum sample Second serum sample Third serum sample
IgM IgG IgM IgG IgM IgG
Summary statistic:b
Geometric mean (GSD) 134.7 (3.1) 321.6 (2.5) 620.5 (2.4) 2437.9 (2.4) 280.7 (1.8) 1045.2 (1.9)
Range 0–12 800 120–7680 200–12 800 480–61 440 50–3200 240–7680
No. (%) of patients with titers:
Above the cut-off valuec 11 (12.2) 12 (13.3) 83 (92.2) 89 (98.9) 34 (37.8) 67 (74.4)
Below the cut-off value, but
four-fold increase in titers
- - 3 (3.3) 1 (1.1) 0 (0) 0 (0)
GSD, geometric standard deviation.
a Serum samples were taken at admission, at 1 week after admission and 3 weeks later.
b Data are inverse titer values.
c Cut-off values were IgM  1:400 and IgG  1:960.
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when patients were stratiﬁed by age group (based on quartile
groupings) and gender.
The outcome was favorable for all patients and no relapse or
death was observed within 6 months after discharge from the
hospital.
4. Discussion
MT has a cosmopolitan distribution, and endemic foci of the
disease are maintained worldwide. However, clinical studies of MT
involving sufﬁciently large numbers of patients remain scarce.16–21
The disease is probably under-diagnosed and largely under-
reported worldwide, due to its frequent mild course and non-
speciﬁc presentation, the limited awareness of physicians, and
because it is often not included in the list of nationally reportable
diseases and is not actively monitored.1–5
The present study, which is one of the largest case-series of MT
reported to date, was a hospital-based active survey of MT, which
re-emerged in a previously known endemic focus on the island of
Evia. The classical rat–ﬂea–rat transmission cycle of R. typhi has
previously been conﬁrmed in the study area, and the bacterium has
been detected and identiﬁed in both rat blood samples and their
ﬂeas.22,23 An ecosystem favorable to the growth of rodent and ﬂea
populations and breaches in rodent control measures are most
likely responsible for the re-emergence of MT in the region. Indeed,
cases occurred throughout the year, with a seasonal frequencyTime to defervescence (days)
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Figure 2. Kaplan–Meier plot of the relationship between antibiotics used and
duration of fever in 90 patients with murine typhus in central Greece.peak in late summer in this study, when climatic conditions in the
region are more favorable for the commensal rat population to
ﬂourish and human exposure to the environment is greater. In
other studies, the highest incidence was observed in May and
June,4,16,19 suggesting that climatic conditions are the main factors
contributing to different seasonal distributions of human cases in
different geographical areas.
Although MT has been described as a disease of mostly urban
or port areas,1–3,6 most cases in the present study occurred in
rural and semi-urban settings, with a peripheral distribution
around the city of Chalkida. Moreover, most patients were men
who had an occupation that required working outdoors in
nature or were involved in agricultural activities, thus being at
high risk for contact with rodents. Changes in vector–host
ecology owing to environmental and human behavior modiﬁca-
tions may be allowing the expansion of R. typhi into rural
areas.24 Regional studies in Spain noted that seroprevalence
rates of R. typhi were not highest in urban areas,25–27 and a peri-
domestic cycle involving dogs and wild rodents and their ﬂeas
was suggested to have contributed to the rural expansion of R.
typhi in those regions.28,29 However, there is no evidence
indicating that such a peri-domestic cycle may have been
involved in our region.
We obtained three serum samples from each patient at various
times after the onset of illness, which enabled us to depict antibody
kinetics during the ﬁrst month following disease onset. Within the
ﬁrst week of illness, the rates of serologic conﬁrmation based on
the IgM and IgG antibody levels were similar but very low in our
patients. In contrast, almost all patients had IgM and IgG
conﬁrmatory levels within the second week following illness
onset. Both IgM and IgG antibody levels had declined in the fourth
week after onset, but the latter sustained conﬁrmatory levels in a
high proportion of the patients. These ﬁndings indicate that the IFA
test is unhelpful for the diagnosis of MT early in the course of
illness and that IgM antibody titers may not offer any advantage
over IgG in the conﬁrmation of the diagnosis. Moreover, a delay in
the rise of antibody titers was noted for the elderly patients in this
study, indicating that early laboratory conﬁrmation of MT should
not be expected in the elderly.
The clinical features of MT observed in this study were
consistent with those reported by others,16–20,30,31 with fever,
headache, and rash being the main and most frequent symptoms
and signs. The frequency of rash in our patients (69%) was similar
to that reported previously in our study region (71%),15 and within
the range of that reported in other large regional cohorts in Greece,
Spain, Croatia, and the USA (62–80%).18–20,30–32 The rash appeared
a median of 4 days after onset of fever and lasted for a median of 3
days. Thus, the appearance and characteristics of rash may aid the
early diagnosis of MT. In our patients the rash was macular or
maculopapular with a centrifugal spread over the trunk, sparing
G. Chaliotis et al. / International Journal of Infectious Diseases 16 (2012) e591–e596 e595the palms and soles. Petechial lesions, which have scarcely been
reported in the literature,18,19 were not observed in this study.
The usefulness of the classical triad of fever, headache, and rash
as a clinical diagnostic tool for MT has been questioned by other
researchers.19 However, our patients presented with continuous
fever of abrupt onset, followed by frontal headache and then rash,
with median time lags of 2 days between the onsets of each
symptom. The clinical triad was completed in 64% of the patients
within the ﬁrst 2 days following admission. Thus, our data
illustrate that the classical triad is a valuable early indicator of MT.
Several ocular manifestations associated with MT were recently
reported in Tunisia.33 We noted conjunctivitis in 21% of our
patients. Therefore, complete ophthalmic examinations in patients
suspected of MT may also be helpful in the early clinical diagnosis
of the disease.
In agreement with other studies,16,18–21,30,31 we found that
elevated aminotransferases and hypoalbuminemia were promi-
nent biochemical abnormalities occurring in most of the patients.
Hyponatremia, which has been reported with a varying frequency
of 18% to 66% in other studies,16,19,20,30,31 was noted in 36% of our
patients. R. typhi-induced systemic vasculitis allows extravasation
of protein and electrolytes,2 consistent with the hypoalbuminemia
that was frequently observed. Elevation of aminotransferases is
possibly due to hepatocyte and biliary injury adjacent to inﬂamed
microvasculature.19
The main hematological ﬁndings observed in this study were
also consistent with those noted by others,18,19,30,31 although their
relative frequencies are greatly variable in the literature.31 Our
patients presented mostly with normal white blood cell counts
(63%), thrombocytopenia (81%), and a high erythrocyte sedimen-
tation rate (93%). Thrombocytopenia, as well as leukopenia, is
consistent with the consumption of platelets and leukocytes at the
site of vascular inﬂammation.2
In general, MT is perceived as a mild disease. However, a
signiﬁcant proportion of our patients (26%), mainly elderly
patients, presented one or more complications in different organs.
A similarly high frequency of complications in patients with MT
has been reported in Texas (27%).34 These ﬁndings demonstrate
that MT has the potential to cause signiﬁcant morbidity.
Pulmonary involvement, mainly manifested with interstitial
inﬁltrations, was noted in 17% of our patients, which is higher than
usually reported (6–12%).18,35 Interstitial pulmonary inﬁltrates on
chest radiography could be attributed to serum leakage from the
damaged capillaries due to R. typhi invasion.2
Neurological ﬁndings have been reported in 15% to 45% of adult
patients.16,19 In this study, 11% of the patients presented with
stupor or coma. Aseptic meningitis and meningoencephalitis,
which have infrequently been reported as delayed neurological
manifestations of MT,36 were not noted in our patients. Neverthe-
less, physicians practicing in or near R. typhi-endemic areas need to
consider MT in the differential diagnosis of patients with fever,
rash, and neurological manifestations.
Acute renal failure is not uncommon in patients with MT,20,31,34
and 8% of our patients had this complication. Renal failure could
occur as a result of kidney hypoperfusion secondary to loss of
intravascular volume through increased vascular permeability, or
perivascular interstitial nephritis.2
Doxycycline is the drug of choice for MT in adults and children,
excluding pregnant women.2,4 Large clinical series from Greece
and the USA found that doxycycline resulted in a mean time to
defervescence of 3 days,16,20 a ﬁnding that is also supported by the
present study. Chloramphenicol is considered to be effective as an
alternative antibiotic when doxycycline is contraindicated,2,4 but it
is less efﬁcient than doxycycline in terms of time to apyrexia,37 and
frequent relapses of the disease have been reported.38 Quinolones
are also considered to be acceptable alternatives.2–4 However,ciproﬂoxacin has been noted to be less efﬁcient than doxycycline
with respect to duration of fever.37 In this study, oﬂoxacin was
found to be less efﬁcient than doxycycline. Moreover, a poor
response to ciproﬂoxacin in patients with MT has been reported,39
and quinolone treatment was recently stated to have a ‘deleterious
effect’ for the treatment of other rickettsial diseases.40 Combina-
tions of doxycycline with chloramphenicol or ciproﬂoxacin have
also been used in clinical practice, but did not improve the
effectiveness of doxycycline.37 Similarly, in this study, oﬂoxacin
plus doxycycline did not appear to provide any advantage over
doxycycline alone in terms of duration of fever.
This study has certain limitations. First, it was a hospital-based
study and a potential selection bias towards including more severe
cases of MT may exist. Second, our case deﬁnition relied on
serological testing; thus, we cannot completely exclude the
possibility that we may have included cases of R. felis infection,
whose clinical manifestations closely resemble those of MT.
However, no R. felis case has been reported in Greece to date.
Finally, given the observational nature of the study, we had no
control over the different treatment options received by our study
patients. Sample sizes were biased towards treatment with
doxycycline and few patients were treated with oﬂoxacin or
doxycycline plus oﬂoxacin, but our analysis did detect a statisti-
cally signiﬁcant difference in times to defervesce. Although this
difference is not likely to derive either from a varying age
distribution or from differences in treatment initiation times, we
cannot exclude the possibility that residual confounding by other
factors could have affected the reported ﬁndings.
In conclusion, the early diagnosis of MT needs a high index of
suspicion and depends on the ability of clinicians to identify
speciﬁc clinical and laboratory features of the disease. The results
of the present study provide enhanced knowledge of the clinico-
epidemiological proﬁle of MT, increasing the ability of clinicians to
promptly respond to the disease. The study ﬁndings also
emphasize that MT has the potential to cause signiﬁcant
morbidity. Awareness of the disease in endemic areas and the
early administration of effective treatment are key factors to
prevent potentially severe complications of MT.
Conﬂict of interest: The authors have no conﬂicts of interest to
disclose.
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